Active	Status	Sponsor type	Region	Phase	Filter
3 Active 8 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ricke, Jens
DEMAND, NCT04224636: Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab	Recruiting	2	106	Europe	Atezolizumab Injection, Bevacizumab Injection, Chemoembolisation (TACE)	Ludwig-Maximilians - University of Munich	Hepatocellular Carcinoma Non-resectable	03/25	03/25
NCT04238637 / 2018-004778-81: Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)	Recruiting	2	50	Europe	Durvalumab, Other Name: MEDI4736, Tremelimumab, Study treatment	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, AstraZeneca	Intrahepatic Cholangiocarcinoma	12/25	12/25
HOMIE-166, NCT05451862: Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma.	Recruiting	2	73	Europe	Holmium-166 treatment, QuiremSpheresTM Holmium-166 Microspheres, Holmium-166 work-up, QuiremScoutTM Holmium-166 Microspheres	Terumo Europe N.V.	Hepatocellular Carcinoma	01/31	01/31